Genentech cancer med nabs Breakthrough status

Share this article:

Roche subsidiary Genentech scored a breakthrough-therapy designation for its experimental Phase-I immuno-oncology drug MPDL3280A. The anticipated patient population is comprised of previously treated metastatic urothelial bladder cancer patients who test positive for PD-L1, which stands for programmed death ligand-1. The test is being developed by parent company Roche.

Genentech said in a statement Saturday that results prompting the FDA's breakthrough label showed tumors shrank in 43% of patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.